echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Genome-wide screening identifies novel targets for the treatment of sorafenib-resistant hepatocellular carcinoma

    Genome-wide screening identifies novel targets for the treatment of sorafenib-resistant hepatocellular carcinoma

    • Last Update: 2022-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    A study led by Xiujun Cai screened the whole genome of hepatoma cells (HepG2) under sorafenib treatment by the CRISPR/cas9 system, and screened the dominant gene KEAP1 for sorafenib resistance


    Using bioinformatics tools and experimental validation, such as qPCR, FGF21 was found to be the most relevant downstream molecule of Nrf2 in the context of sorafenib resistance in hepatocellular carcinoma


    The research was published in the journal Science China Life Sciences




    Provided by Scientific China Press


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.